Latin American open-label study with rabeprazole in patients with functional dyspepsia

This multicenter, open-label study assessed the clinical efficacy and toler ability of the proton-pump inhibitor rabeprazole 20 mg once daily in 189 pa tients with functional dyspepsia and normal findings on upper endoscopy. Th e clinical efficacy rate was 86% after only 4 weeks of treatment, and sympt oms remained under control at the end of 4 weeks without treatment. Rabepra zole was well tolerated and was associated with a low incidence (8%) of mil d, transient adverse events.